<sup>68</sup>Ga PSMA Uptake at Roux-en-Y Eso-jejunostomy Junction Mimicking the Recurrence of Gastric Carcinoma in PET/CT
PDF
Cite
Share
Request
Interesting Image
P: 63-66
February 2021

68Ga PSMA Uptake at Roux-en-Y Eso-jejunostomy Junction Mimicking the Recurrence of Gastric Carcinoma in PET/CT

Mol Imaging Radionucl Ther 2021;30(1):63-66
1. University of Health and Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Turkey
2. University of Health and Sciences Turkey, İstanbul Training and Research Hospital, Department of Pathology, İstanbul, Turkey
3. University of Health and Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Surgery, Istanbul, Turkey
No information available.
No information available
Received Date: 10.11.2019
Accepted Date: 02.04.2020
Publish Date: 09.02.2021
PDF
Cite
Share
Request

ABSTRACT

A 67-year-old male patient had undergone total gastrectomy and Roux-en-Y eso-jejunostomy 3 years ago for the treatment of tubular adenocarcinoma located at the corpus of the stomach. The patient was diagnosed with Gleason score 8 (4+4) metastatic prostate cancer during the follow-up period and received hormone therapy. Owing to his elevated prostate-specific antigen levels (77 ng/mL), his clinician referred him gallium-68 (68Ga) prostate-specific membrane antigen 11 (PSMA) positron emission tomography/computed tomography (PET/CT) for restaging. PET/CT showed multiple 68Ga PSMA receptor-positive skeletal lesions and linear PSMA activity at the eso-jejunostomy junction. He was then referred to undergo 18fluorine-fluorodeoxyglucose (18F-FDG) PET/CT to screen for gastric carcinoma recurrence. PET/CT images demonstrated no 18F-FDG avid lesion. However, endoscopy and biopsy performed with samples from the eso-jejunostomy junction revealed superficial benign squamous epithelial fragments.

Keywords:
68Ga-PSMA
18F-FDG
PET/CT
gastric carcinoma
prostate carcinoma

References

1
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40:486-495.
2
Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun 2016;37:1169-1179.
3
Kirchner J, Schaarschmidt BM, Sawicki LM, Heusch P, Hautzel H, Ermert J, Rabenalt R, Antoch G, Buchbender C. Evaluation of Practical Interpretation Hurdles in 68Ga-PSMA PET/CT in 55 Patients: Physiological Tracer Distribution and Incidental Tracer Uptake. Clin Nucl Med 2017;42:322-327.
4
Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics 2018;38:200-217.
5
Holderman WH, Jacques JM, Blackstone MO, Brasitus TA. Prostate cancer metastatic to the stomach. Clinical aspects and endoscopic diagnosis. J Clin Gastroenterol 1992;14:251-254.
6
Solis Lara HE, Villarreal Del Bosque N, Sada Treviño MA, Yamamoto Ramos M, Argueta Ruiz RDC. Gastric Metastasis of Prostate Cancer as an Unusual Presentation Using 68Ga-Prostate-Specific Membrane Antigen PET/CT. Clin Nucl Med 2018;43:156-159.
7
Onitilo AA, Engel JM, Resnick JM. Prostate carcinoma metastatic to the stomach: report of two cases and review of the literature. Clin Med Res 2010;8:18-21.
8
Hong KP, Lee SJ, Hong GS, Yoon H, Shim BS. Prostate cancer metastasis to the stomach. Korean J Urol 2010;51:431-433.
9
Shetty D, Patel D, Le K, Bui C, Mansberg R. Pitfalls in Gallium-68 PSMA PET/CT Interpretation-A Pictorial Review. Tomography 2018;4:182-193.
10
Gordon IO, Tretiakova MS, Noffsinger AE, Hart J, Reuter VE, Al-Ahmadie HA. Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol 2008;21:1421-1427.